A study evaluating outcomes of the prostatic urethral lift (PUL; UroLift System) in clinical practice show that the efficacy and safety documented in the selected group of men enrolled in clinical trials is maintained across the broader spectrum of patients who present for treatment of symptomatic BPH in the real-world setting.
Cheryl Guttman Krader
Neoadjuvant chemohormonal therapy warrants consideration in the management of men undergoing radical prostatectomy for clinically localized high-risk prostate cancer, said James Eastham, MD, at the American Society of Clinical Oncology annual meeting in Chicago.
Results of a phase III trial show the benefit of darolutamide (Nubeqa) in reducing the risk of metastases or death compared with placebo in men with nonmetastatic castration-resistant prostate cancer.
Race does not affect oncologic response to treatment with docetaxel (Taxotere)/prednisone in men with metastatic castrate-resistant prostate cancer, according to research presented at the American Society of Clinical Oncology annual meeting in Chicago.
Adding enzalutamide (XTANDI) to androgen deprivation therapy significantly improves outcomes for men with metastatic hormone-sensitive prostate cancer regardless of whether they received prior chemotherapy.
18F-DCFPyL PET/CT imaging demonstrated excellent performance in identifying regional or distant metastases in men with prostate cancer in the prospective OSPREY study.
The high-power holmium laser with Moses technology (Lumenis Moses Pulse 120H) and the super-pulse thulium fiber laser (SPTF) have a similar ablative effect when operated at the same power, but when evaluated at maximal dusting settings, the SPTF laser seems to hold an advantage for greater efficiency, according to research reported at the AUA annual meeting in Chicago.
A significant proportion of men who progress radiologically while on the androgen receptor inhibitor enzalutamide (XTANDI) do not meet standard criteria for PSA progression, reported Fred Saad, MD.
Following a program that combines a low carbohydrate diet and modest walking may be an effective strategy for blocking many of the adverse metabolic effects of androgen deprivation therapy, according to findings of a randomized controlled trial.
Patients with ureteral stents are rarely lost to follow-up, but the risk is increased when patients are stented in an emergent setting rather than as part of an elective procedure, Yale University urologists reported at the 2018 World Congress of Endourology in Paris.